Essay On Cancer Chemoprevention

1663 Words4 Pages

I have elected to transcribe my proposal argument on issues regarding cancer chemoprevention. I selected this topic because reasonably minute devotion has been given to cancer chemoprevention research in ethical writings, particularly in relation to the huge quantity of moral studies in cancer treatment exploration. Cancer chemoprevention trials test the ability and care of medicinal agents in averting cancer before its manifestation. I believe that phase III chemoprevention issues can be less prevalent by simply ensuring enhanced communication and etiquette between researchers and investigators.
Chemoprevention requires treatments that are administered to presumably healthy, asymptomatic subjects who do not have cancer, but do have risk factors associated with an increased probability to cultivate the cancer which the experimental intervention is theorized to condense. So, chemoprevention research involves at-risk research subjects who are neither patients diagnosed with disease, as in treatment trials, or typical healthy volunteers. There is a growing interest and investment in research on cancer chemoprevention. Several major cancer chemoprevention trials have been conducted in the United States, including trials testing the effectiveness of tamoxifen, both alone and later compared to raloxitene, to prevent primary invasive breast cancer; finasteride to prevent prostate cancer; and beta-carotene to prevent lung cancer.
While both cancer treatment and chemoprevention trials involve agents that can cause side effects in individuals, chemoprevention trials diverge from treatment trials with respect to the unit of potential benefit. In trials of cancer treatment or of “adjuvant therapies” (secondary prevention), subjects either hav...

... middle of paper ...

...k.

To sum things up, the ethical demeanor of research involves respect for the safety and rights of subjects during the sequence of the trial. This includes protecting privacy and confidentiality, monitoring the condition of research subjects to assure their safety, terminating study participation in the case of hostile events, and notifying enrolled subjects about new risks, benefits, or other information that may bear upon subjects’ decisions to continue enrollment in the research. As new evidence shows itself, trial investigators and data safety monitoring boards (DSMBs) can alter the study plan, initiate notice of enrolled subjects, make changes to the informed consent policies, or stop the trials earlier than intended. Investigators should soon classify a technique for ensuring effective communication between the IRB and DSMB throughout these studies.

.

Open Document